Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03838042
Title INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University Hospital Heidelberg

brain ependymoma

rhabdoid cancer


bone sarcoma

high grade glioma

embryonal rhabdomyosarcoma


atypical teratoid rhabdoid tumor

alveolar rhabdomyosarcoma



Entinostat + Nivolumab

Age Groups: adult | senior
Covered Countries FRA | DEU | AUT

Facility Status City State Zip Country Details
Sydney Children's Hospital Recruiting Randwick New South Wales 2031 Australia Details
Children's Hospital at Westmead Recruiting Westmead New South Wales 2145 Australia Details
Royal Children's Hospital Recruiting Parkville Victoria 3052 Australia Details
Perth Children's Hospital Recruiting Nedlands Western Australia 6009 Australia Details
St. Anna Children's Hospital Recruiting Vienna 1090 Austria Details
Institut Curie Recruiting Paris 75005 France Details
Augsburg University Hospital Recruiting Augsburg 86156 Germany Details
Charité University Medicine Berlin Recruiting Berlin Germany Details
Essen University Hospital Recruiting Essen Germany Details
Hannover Medical School Recruiting Hannover Germany Details
Hopp Children's Cancer Center Heidelberg (KiTZ) Recruiting Heidelberg 69120 Germany Details
Prinses Máxima Centrum Recruiting Utrecht Netherlands Details
Karolinska Institute Recruiting Stockholm Sweden Details
Children's Hospital Zurich Recruiting Zurich 8032 Switzerland Details
*Shaded cells indicate that there was no data available from for the field